Table 1 Metastasis’ risk related to clinical and histopathological variables
From: Usefulness of IMP3 and FOXP3 to predict metastasis of cutaneous melanomas
Variables | Without metastasis | With metastasis | OR (CI95%) | p | |
|---|---|---|---|---|---|
Gender | Female | 42(79%) | 11(21%) | 1.00 | |
Male | 43(73%) | 16(27%) | 1.30 (0.60–2.81) | 0.495 | |
Age* | ≤61.5 | 55(85%) | 10(15%) | 1.00 | |
>61.5 | 30(64%) | 17(36%) | 2.35 (1.07–5.13) | 0.032 | |
Subtype* | SS | 66(92%) | 6(8%) | 1.00 | |
Ac | 9(53%) | 8(47%) | 5.65 (1.95–16.27) | 0.001 | |
Nd | 3(25%) | 9(75%) | 9.00 (3.20–25.28) | <0.001 | |
LM | 7(64%) | 4(36%) | 4.36 (1.23–15.46) | 0.022 | |
Breslow* | [0–1] | 62(95%) | 3(5%) | 1.00 | |
(1–4] | 16(62%) | 10(38%) | 8.33 (2.29–30.27) | 0.001 | |
>4 | 7(33%) | 14(67%) | 14.44 (4.15–50.26) | <0.001 | |
Ulceration* | Absence | 70(90%) | 8(10%) | 1.00 | |
Presence | 15(44%) | 19(56%) | 5.44 (2.38–12.44) | <0.001 | |
Mitosis* | 0 | 58(97%) | 2(3%) | 1.00 | |
[1–5] | 16(55%) | 13(45%) | 13.44 (3.03–59.59) | 0.001 | |
>5 | 11(48%) | 12(52%) | 15.65 (3.50–69.93) | 0.001 | |
IMP3 | ≤2+ | 76(76%) | 24(24%) | 1.00 | |
>2+ | 9(75%) | 3(25%) | 1.04 (0.31–3.45) | 0.947 | |
FOXP3 | ≤2+ | 75(76%) | 24(24%) | 1.00 | |
>2+ | 10(77%) | 3(23%) | 0.95 (0.28–3.16) | 0.936 | |
Regression* | Absence | 37(65%) | 20(35%) | 1.00 | |
Presence | 48(87%) | 7(12%) | 0.36 (0.15–0.85) | 0.021 | |